Record NNP B-NP O
date NN I-NP O
: : O O
2077-07-30 CD O B-DATE
FOLLOW-UP JJ B-NP O
VISIT NNP I-NP O
: : O O
CAD NN B-NP O
, , O O
DM NNP B-NP O
, , O O
HTN . O O
HPI NNP B-NP O
: : O O
The DT B-NP O
pt NN I-NP O
is VBZ B-VP O
a DT B-NP O
71 CD I-NP B-AGE
yo NNP I-NP O
female NN I-NP O
here RB B-ADVP O
for IN B-PP O
follow-up JJ B-NP O
visit NN I-NP O
for IN B-PP O
DM NNP B-NP O
monitoring NN I-NP O
, , O O
lipid JJ B-NP O
management NN I-NP O
, , O O
htn RB B-ADVP O
. . O O
She PRP B-NP O
was VBD B-VP O
hospitalized VBN I-VP O
for IN B-PP O
acute JJ B-NP O
MI NNP I-NP O
last JJ I-NP O
December NNP I-NP B-DATE
and CC O O
is VBZ B-VP O
being VBG I-VP O
followed VBN I-VP O
by IN B-PP O
cardiology NN B-NP O
. . O O
Since IN B-PP O
her PRP$ B-NP O
last JJ I-NP O
follow-up JJ I-NP O
the DT B-NP O
patient NN I-NP O
has VBZ B-VP O
had VBN I-VP O
no DT B-NP O
episodes NNS I-NP O
of IN B-PP O
exertional JJ B-NP O
or CC O O
rest VB B-VP O
chest NN B-NP O
pain NN I-NP O
, , O O
no DT B-NP O
DOE NNP I-NP O
or CC I-NP O
SOB. NNP I-NP O
She PRP B-NP O
was VBD B-VP O
visiting VBG I-VP O
her PRP$ B-NP O
relatives NNS I-NP O
in IN B-PP O
Oregon NNP B-NP B-STATE
this DT B-NP O
month NN I-NP O
and CC O O
did VBD B-VP O
have VB I-VP O
one CD B-NP O
episode NN I-NP O
of IN B-PP O
SVT NNP B-NP O
in IN B-PP O
setting VBG B-VP O
of IN B-PP O
viral JJ B-NP O
URI. NNP I-NP O
Experienced NNP I-NP O
sudden JJ I-NP O
onset NN I-NP O
of IN B-PP O
palpitations NNS B-NP O
with IN B-PP O
discomfort NN B-NP O
, , O O
lasted VBD B-VP O
30 CD B-NP O
minutes NNS I-NP O
without IN B-PP O
chest NN B-NP O
pain NN I-NP O
, , O O
lightheadedness NN B-NP O
or CC I-NP O
diaphoresis NN I-NP O
and CC O O
then RB O O
resolved VBD B-VP O
spontaneously RB B-ADVP O
. . O O
She PRP B-NP O
has VBZ B-VP O
had VBN I-VP O
no DT B-NP O
further JJ I-NP O
episodes NNS I-NP O
. . O O
She PRP B-NP O
has VBZ B-VP O
been VBN I-VP O
compliant JJ B-ADJP O
with IN B-PP O
her PRP$ B-NP O
medications NNS I-NP O
over IN B-PP O
the DT B-NP O
last JJ I-NP O
few JJ I-NP O
months NNS I-NP O
and CC O O
has VBZ B-VP O
not RB I-VP O
experienced VBN I-VP O
any DT B-NP O
side NN I-NP O
effects NNS I-NP O
; : O O
however RB B-ADVP O
, , O O
when WRB B-VP O
asked VBN I-VP O
directly RB B-ADVP O
, , O O
has VBZ B-VP O
had VBN I-VP O
2 CD B-NP O
or CC I-NP O
3 CD I-NP O
episodes NNS I-NP O
of IN B-PP O
lightheadedness NN B-NP O
in IN B-PP O
morning NN B-NP O
with IN B-PP O
abrupt JJ B-NP O
position NN I-NP O
changes NNS I-NP O
, , O O
nothing NN B-NP O
long-lasting JJ I-NP O
and CC O O
no DT B-NP O
near IN B-PP O
syncope NN B-NP O
. . O O
Pt JJ B-NP O
reports NNS I-NP O
blood NN I-NP O
sugars NNS I-NP O
by IN B-PP O
finger NN B-NP O
stick NN I-NP O
at IN B-PP O
home NN B-NP O
of IN B-PP O
100-140s CD B-NP O
generally RB I-NP O
. . O O
Has VBZ B-VP O
had VBD I-VP O
good JJ B-NP O
control NN I-NP O
by IN B-PP O
her PRP$ B-NP O
accounts NNS I-NP O
over IN B-PP O
last JJ B-NP O
few JJ I-NP O
months NNS I-NP O
. . O O
Was VBD B-VP O
unaware JJ I-VP O
of IN B-PP O
results NNS B-NP O
of IN B-PP O
May NNP B-NP B-DATE
blood NN I-NP O
draw VBP B-VP O
with IN B-PP O
increase NN B-NP O
in IN B-PP O
HA1C NNP B-NP O
of IN B-PP O
8.0. VBG B-NP O
Medical JJ B-NP O
problems NNS I-NP O
: : O O
SVT . O O
LGI NNP B-NP O
BLEEDING NN I-NP O
SMOKING VBG O O
H. NNP B-NP O
PYLORI NNP I-NP O
NIDDM . O O
Coronary JJ B-NP O
artery NN I-NP O
disease NN I-NP O
Myocardial JJ B-NP O
infarction NN I-NP O
Current JJ B-NP O
medications NNS I-NP O
: : O O
MICRONASE NNP B-NP O
5 CD I-NP O
MG NNP I-NP O
PO NNP I-NP O
QD . O O
RANITIDINE NNP B-NP O
HCL NNP I-NP O
150MG VBD B-VP O
1 CD B-NP O
Tablet( NN I-NP O
s VBZ B-VP O
) -RRB- B-NP O
PO NN I-NP O
BID NNS I-NP O
Take VBP B-VP O
as IN B-SBAR O
directed VBN B-UCP O
ATENOLOL NNP B-NP O
25MG VBD B-VP O
3 CD B-NP O
Tablet( NN I-NP O
s VBZ B-VP O
) -RRB- B-NP O
PO NNP I-NP O
QD NNP I-NP O
One CD I-NP O
25 CD I-NP O
and CC O O
one CD B-NP O
50 CD I-NP O
mg JJ I-NP O
tab NN I-NP O
daily RB B-ADVP O
90 CD B-NP O
day( NN I-NP O
s VBZ B-VP O
) -RRB- O O
ZOCOR NN B-NP O
( -LRB- I-NP O
SIMVASTATIN NNP I-NP O
) -RRB- I-NP O
20MG . B-VP O
1 CD B-NP O
Tablet( NN I-NP O
s VBZ B-VP O
) -RRB- B-NP O
PO NN I-NP O
QHS NNS I-NP O
Take VBP B-VP O
as IN B-PP O
directed VBN B-NP O
90 CD I-NP O
day( JJ I-NP O
s PRP B-NP O
) -RRB- O O
ZESTRIL NNP B-NP O
( -LRB- I-NP O
LISINOPRIL NNP I-NP O
) -RRB- I-NP O
20MG . B-VP O
1 CD B-NP O
Tablet( NN I-NP O
s VBZ B-VP O
) -RRB- B-NP O
PO NN I-NP O
QD . B-VP O
Take VB I-VP O
as RB I-VP O
directed VBN I-VP O
90 CD B-NP O
day( NN I-NP O
s VBZ B-VP O
) -RRB- O O
AMITRIPTYLINE NNP B-NP O
HCL NNP I-NP O
25MG VBD B-VP O
1 CD B-NP O
Tablet( NN I-NP O
s VBZ B-VP O
) -RRB- B-NP O
PO NN I-NP O
QHS . O O
ECASA NNP B-NP O
( -LRB- I-NP O
ASPIRIN NNP I-NP O
ENTERIC NNP I-NP O
COATED NNP I-NP O
) -RRB- I-NP O
325MG JJ I-NP O
1 CD I-NP O
Tablet( NN I-NP O
s VBZ B-VP O
) -RRB- B-NP O
PO NN I-NP O
QD . O O
PE NN B-NP O
: : O O
bp NN B-NP O
130/72 CD I-NP O
p NN I-NP O
72 CD B-NP O
wt NN I-NP O
213 CD B-NP O
(up NN I-NP O
from IN B-PP O
203 CD B-NP O
) -RRB- O O
chest NN B-NP O
: : O O
CTA NNP B-NP O
B NNP I-NP O
cor NN B-NP O
: : O O
RRR NNP B-NP O
nl , O O
s1 CD B-NP O
s2 NN I-NP O
, , O O
no DT B-NP O
murmurs NNS I-NP O
abd NN B-NP O
: : O O
soft JJ B-NP O
NT NNP I-NP O
ND NNP I-NP O
with IN B-PP O
normal JJ B-NP O
BS NNP I-NP O
ext NN B-NP O
: : O O
normal JJ B-NP O
pulses NNS I-NP O
, , O O
no DT B-NP O
edema NN I-NP O
Labs NNS B-NP O
: : O O
last JJ B-NP O
hemoglobin NN I-NP O
A1C . O O
in IN B-PP O
5/77 CD B-NP B-DATE
of IN B-PP O
8.0, CD B-NP O
gluc NN I-NP O
192 CD B-NP O
, , O O
LDL NNP B-NP O
115 CD I-NP O
, , O O
TG NNP B-NP O
71 CD I-NP O
, , O O
HDL NNP B-NP O
36 CD I-NP O
A/P NNP B-NP O
: : O O
71 CD B-NP B-AGE
yo NNP I-NP O
female NN I-NP O
with IN B-PP O
DM NNP B-NP O
, , O O
HTN NNP B-NP O
, , O O
and CC O O
heart NN B-NP O
disease NN I-NP O
with IN B-PP O
slightly RB B-ADVP O
worsening VBG B-VP O
glycemic JJ B-NP O
and CC I-NP O
lipid JJ I-NP O
control NN I-NP O
when WRB B-ADVP O
tested VBN B-VP O
2 CD B-NP O
months NNS I-NP O
ago RB B-ADVP O
, , O O
perhaps RB B-VP O
related VBN I-VP O
to TO B-PP O
modest JJ B-NP O
weight NN I-NP O
gain NN I-NP O
of IN B-PP O
10 CD B-NP O
lbs NNS I-NP O
. . O O
1 LS B-NP O
. . O O
DM VB B-VP O
- : I-VP O
pt NN B-NP O
with IN B-PP O
rising VBG B-VP O
A1C IN B-PRT O
despite IN B-PP O
good JJ B-NP O
FS NNS I-NP O
at IN B-PP O
home NN B-NP O
. . O O
Given VBN B-VP O
pt NN B-NP O
feels VBZ B-VP O
control NN B-NP O
has VBZ B-VP O
improved VBN I-VP O
since IN B-PP O
last JJ B-NP O
visit NN I-NP O
, , O O
will MD B-VP O
stall VB I-VP O
on IN B-PP O
changing VBG B-VP O
micronase NN B-NP O
until IN B-PP O
next JJ B-NP O
visit NN I-NP O
at IN B-PP O
one CD B-NP O
month NN I-NP O
. . O O
Pt NNP O O
to TO B-VP O
have VB I-VP O
repeat NN B-NP O
a1c NN I-NP O
at IN B-PP O
that DT B-NP O
point NN I-NP O
, , O O
and CC O O
if IN B-PP O
still RB B-NP O
high JJ I-NP O
, , O O
will MD B-VP O
double VB I-VP O
micronase NN B-NP O
. . O O
Good JJ B-NP O
bp JJ I-NP O
control NN I-NP O
on IN B-PP O
zestril NN B-NP O
. . O O
Had VBD B-VP O
microalb NN I-VP O
this DT B-NP O
year NN I-NP O
. . O O
Still RB B-VP O
awaiting VBG I-VP O
visit NN B-NP O
to TO B-VP O
ophthal VB I-VP O
- : O O
gave VBD B-VP O
pt JJ B-NP O
another DT I-NP O
referral NN I-NP O
. . O O
2. CD B-NP O
CAD NN I-NP O
- : O O
pt NN B-NP O
with IN B-PP O
LDL NNP B-NP O
of IN B-PP O
115 CD B-NP O
when WRB B-VP O
previously RB I-VP O
well RB I-VP O
controlled VBN I-VP O
on IN B-PP O
this DT B-NP O
dose NN I-NP O
of IN B-PP O
zocor NN B-NP O
. . O O
After IN B-PP O
negotiation NN B-NP O
with IN B-PP O
patient NN B-NP O
, , O O
have VBP B-VP O
agreed VBN I-VP O
to TO I-VP O
wait VB I-VP O
to TO I-VP O
raise VB I-VP O
dose NN B-NP O
until IN B-PP O
next JJ B-NP O
visit NN I-NP O
as RB B-ADVP O
well RB I-ADVP O
. . O O
Would MD B-VP O
benefit VB I-VP O
from IN B-PP O
30 CD B-NP O
mg JJ I-NP O
tab NN I-NP O
. . O O
Otherwise RB B-VP O
TG . I-VP O
look VB I-VP O
good JJ B-ADJP O
. . O O
Pt NNP O O
with IN B-PP O
episode NN B-NP O
of IN B-PP O
SVT NNP B-NP O
in IN B-PP O
setting VBG B-VP O
of IN B-PP O
viral JJ B-NP O
illness NN I-NP O
. . O O
BP NNP B-NP O
and CC I-NP O
pulse NN I-NP O
will MD B-VP O
tolerate VB I-VP O
small JJ B-NP O
increment NN I-NP O
in IN B-PP O
b-blocker NN B-NP O
. . O O
Given VBN B-VP O
known VBN I-VP O
CAD NN B-NP O
without IN B-PP O
intervention NN B-NP O
, , O O
impt JJ B-ADJP O
to TO B-VP O
control VB I-VP O
SVTs NNP B-NP O
. . I-NP O
Increase NNP I-NP O
atenolol VBD B-VP O
to TO B-PP O
100 CD B-NP O
mg NN I-NP O
QD NN I-NP O
, , O O
keep VB B-VP O
zestril NN B-NP O
at IN B-PP O
current JJ B-NP O
dose NN I-NP O
. . O O
3. DT B-NP O
HM NNP I-NP O
- : O O
pt NN B-NP O
refuses VBZ B-VP O
mammogram NN B-NP O
. . O O
She PRP B-NP O
continues VBZ B-VP O
to TO I-VP O
be VB I-VP O
suspicious JJ B-ADJP O
that IN B-PP O
screening NN B-NP O
tests NNS I-NP O
are VBP B-VP O
experimental JJ B-ADJP O
and CC O O
given VBN B-VP O
her PRP$ B-NP O
age NN I-NP O
"would VBD B-VP O
n't RB I-VP O
change VB I-VP O
anything NN B-NP O
. . O O
" '' O O
Discussed VBN B-NP O
baseline NN I-NP O
bone NN I-NP O
density NN I-NP O
test NN I-NP O
, , O O
and CC O O
she PRP B-NP O
has VBZ B-VP O
agreed VBN I-VP O
to TO I-VP O
consider VB I-VP O
this DT B-NP O
. . O O
Refused VBN B-VP O
colonscopy NN B-NP O
at IN B-PP O
this DT B-NP O
point NN I-NP O
. . O O
